Login
Israel-Hamas Conflict
Airstrike
World Cup
Military
Social Media
South America
Immigration
Donald Trump
Stock Markets
Education
Drones
Artificial Intelligence
Soccer
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Presidio Medical wins FDA IDE approval for neuromodulation trial, names new CFO

Summary by medicaleconomics.com
The FDA’s IDE approval allows Presidio to initiate a randomized, controlled trial in the United States and Australia to evaluate the safety and efficacy of its ULF neuromodulation technology

2 Articles

All
Left
Center
1
Right
medicaleconomics.commedicaleconomics.com
Center

Presidio Medical wins FDA IDE approval for neuromodulation trial, names new CFO

The FDA’s IDE approval allows Presidio to initiate a randomized, controlled trial in the United States and Australia to evaluate the safety and efficacy of its ULF neuromodulation technology

Read Full Article
Medical Device NetworkMedical Device Network

Presidio Medical granted IDE approval for neuromodulation platform

Presidio Medical has received an IDE approval from the FDA, enabling a pivotal study of its neuromodulation platform.The post Presidio Medical granted IDE approval for neuromodulation platform appeared first on Medical Device Network.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

medicaleconomics.com broke the news in on Thursday, June 12, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States

United States

News
For You
SearchBlindspotLocal